Endocrine Peptide Test Market Report 2025

This Endocrine Peptide Test market report provides a comprehensive analysis of the market’s characteristics, size, and growth, including segmentation, regional and country-level breakdowns, competitive landscape, market shares, trends, and strategies. It also tracks historical and forecasted market growth across various geographies.

The endocrine peptide test market size has grown strongly in recent years. It will grow from $9.11 billion in 2024 to $9.97 billion in 2025 at a compound annual growth rate (CAGR) of 9.5%. The growth in the historic period can be attributed to increasing government spending, rising prevalence of diabetes, decreasing level of immunity in people across the world, high risk of contracting any chronic diseases, and rising government initiatives.

The endocrine peptide test market size is expected to see strong growth in the next few years. It will grow to $14.22 billion in 2029 at a compound annual growth rate (CAGR) of 9.3%. The growth in the forecast period can be attributed to increasing demand for endocrine peptide test, growth in research and development activities, rise in number of lifestyle diseases, increasing geriatric population, and rising prevalence of diabetes amongst the masses. Major trends in the forecast period include advancement in the endocrine testing method, advancements in product technologies, increasing research and development activities to develop novel testing solutions, growing number of product approval, and shift towards preventive healthcare.

The growing prevalence of diabetes is expected to drive the expansion of the endocrine peptide test market. Diabetes refers to a range of conditions characterized by elevated blood sugar (glucose) levels. The rise in diabetes cases is attributed to factors such as poor diets, sedentary lifestyles, genetic factors, and an aging population. Endocrine peptide tests, including hemoglobin A1c, fasting plasma glucose, and C-peptide tests, are used to diagnose diabetes, monitor glucose levels, and evaluate insulin production and sensitivity. For example, in June 2024, the National Health Service (NHS), a UK-based government agency, reported a notable increase in the number of individuals under 40 diagnosed with diabetes, rising from 173,166 in 2022 to 216,440 in 2023. This significant increase highlights the concerning trend of rising diabetes cases among younger individuals. Therefore, the increasing prevalence of diabetes is fueling the growth of the endocrine peptide test market.

Leading companies in the endocrine peptide test market are advancing immunoassay testing systems to enhance accuracy, sensitivity, and speed. These systems employ antibodies to detect and quantify specific peptides in blood or urine samples, providing healthcare professionals with essential insights into hormone levels and endocrine function. For example, Siemens Healthineers introduced the Atellica CI Analyzer in July 2023, a compact system capable of immunoassay and clinical chemistry testing, including endocrine peptide assays. It features a reproductive endocrinology menu with tests such as anti-Mullerian hormone (AMH) for ovarian reserve assessment and sFlt-1 and PlGF for preeclampsia prognosis. With a capacity of up to 1000 tests per hour, the Atellica CI Analyzer ensures rapid and consistent delivery of high-quality results, supporting laboratories in meeting evolving testing demands.

In October 2022, Tolmar, a US-based pharmaceutical company, acquired Jatenzo from Clarus Therapeutics to bolster its portfolio in pediatric endocrinology and men's health. Jatenzo, a testosterone replacement therapy, complements Tolmar's specialty pharmaceutical products, enhancing their offerings for individuals with endocrine disorders. Clarus Therapeutics, known for developing therapies in this field, facilitated the acquisition, expanding Tolmar's market presence and therapeutic capabilities.

Major companies operating in the endocrine peptide test market are Siemens AG, F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Merck KGaA, Becton Dickinson and Company, Laboratory Corporation of America Holdings (LabCorp), Quest Diagnostics Incorporated, Agilent Technologies Inc., Illumina Inc., bioMérieux SA, Bio-Rad Laboratories Inc., DiaSorin S.p.A., Sciex, Bio-Techne Corporation, Invitae Corporation, ARUP Laboratories, Genova Diagnostics, Boston Heart Diagnostics Corporation, Immunodiagnostic Systems Ltd., Mayo Clinic Laboratories.

North America was the largest region in the endocrine peptide test market in 2024. The regions covered in the endocrine peptide test market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the endocrine peptide test market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The endocrine peptide test is a diagnostic procedure used to assess levels of specific peptides in blood or urine, crucial for monitoring the endocrine system's function and detecting related disorders. It primarily focuses on measuring peptide hormones in blood to diagnose and track endocrine disorders.

Key tests in the endocrine peptide market include dehydroepiandrosterone sulfate (DHEAS), progesterone, luteinizing hormone, thyroid prolactin, estradiol, human chorionic gonadotropin, thyroid-stimulating hormone, among others. The DHEAS test specifically measures DHEAS levels in the bloodstream. Technologies employed include mass spectroscopy, immunoassay, chromatography, nucleic acid-based methods, and others. End users include clinics, healthcare centers, hospitals, and commercial laboratories.

The endocrine peptide test market research report is one of a series of new reports that provides endocrine peptide test market statistics, including the endocrine peptide test industry global market size, regional shares, competitors with endocrine peptide test market share, detailed endocrine peptide test market segments, market trends, and opportunities, and any further data you may need to thrive in the endocrine peptide test industry. These endocrine peptide test market research reports deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The endocrine peptide test market includes revenues earned by entities by providing services such as diagnostic testing, laboratory analysis, research studies, and clinical evaluations. The market value includes the value of related goods sold by the service provider or included within the service offering. The endocrine peptide test market also includes sales of diagnostic kits, reagents, testing instruments, and laboratory equipment. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.